Celcuity

Celcuity, Inc. is cellular analysis company. The company discovers new cancer sub-types and commercializing diagnostic tests designed to improve the clinical outcomes of cancer patients treated with targeted therapies. Its proprietary CELx diagnostic platform is the commercially ready technology that uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the targeted therapy that treats it. The company was founded by Brian F. Sullivan and Lance G. Laing in January 2012 and is headquartered in Minneapolis, MN.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Celcuity reports strong Q4 performance with Phase 3 trial success

Celcuity's Q4 2022 earnings call showcased positive performance, with the initiation of a significant Phase 3 clinical trial and promising efficacy data.
While facing challenges such as increased expenses and potential trial delays, the company's strengths in innovation and financial stability position it well for future growth.
By leveraging opportunities in expanding studies, engaging with payers, and optimizing development strategies, Celcuity can navigate challenges and drive continued success in the oncology market.

Celcuity reports Q1 loss, showcases breast cancer trial progress

Celcuity's Q1 2023 performance reflects a focus on advancing innovative treatments for breast cancer, supported by positive clinical data and a robust pipeline.
While facing financial challenges with increased operating expenses and a net loss, the company maintains a strong cash position for ongoing operations and future growth.
Opportunities lie in leveraging clinical advancements to drive regulatory progress, expand the product portfolio, and capitalize on strategic growth initiatives.

Celcuity reports Q2 loss, progresses on breast cancer trial

Celcuity's Q2 2023 performance reflects ongoing investments in the gedatolisib trial and financial stability.
While facing challenges in trial execution and financial losses, the company's strengths lie in promising trial results and strong cash reserves.
Opportunities for Celcuity include breakthroughs in breast cancer treatment, strategic partnerships, and market expansion.
Overall, Celcuity's progress in the Phase III trial signals potential for growth and innovation in the oncology space.

Celcuity reports Q3 loss, progresses in cancer trials and funding

Celcuity's financials show a net loss but strong cash reserves, while progress in trials indicates a focus on cancer treatment development.
Challenges lie in financial performance and trial outcomes, but opportunities exist in upcoming data releases and new trial initiatives.

Celcuity progresses on gedatolisib development with strong financial backing

Celcuity's earnings call highlighted advancements in gedatolisib development and the addition of a new Chief Commercial Officer, bolstering its leadership team.
While facing challenges in upcoming data releases and addressing analyst inquiries, the company remains well-positioned with strong financial backing.

Celcuity reports progress in breast cancer trial despite financial challenges

Celcuity's Q1 2024 performance showcased progress in key trials and promising treatment efficacy.
While facing financial challenges with increased R&D expenses, the company maintains a strong cash position.
Opportunities lie in leveraging positive trial outcomes and exploring strategic partnerships for future growth.

Celcuity reports Q2 loss, advances cancer therapies amid financial growth

Celcuity's Q2 2024 performance reflects a mix of financial strength and operational progress in advancing cancer therapies
While facing challenges in study timelines and competitive landscape, the company's strategic initiatives position it well for future growth
Opportunities lie in novel treatment combinations, strong financial footing, and market interest in Celcuity's clinical advancements

Celcuity reports Q3 loss, advances gedatolisib in oncology landscape

Celcuity's Q3 performance reflects increased expenses but a strong financial position, with promising developments in gedatolisib's clinical progress.
While facing challenges in expenses and market competition, the company has opportunities to leverage positive feedback and upcoming data releases.
Overall, Celcuity's strategic focus on gedatolisib's potential in oncology presents a pathway for growth and market differentiation.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Median overall survival (OS) among patients with HR+, HER2- advanced breast cancer who were treatment-naïve in the advanced setting was 77.3 months

Celcuity Presents Overall Survival Data from Phase 1b Study Evaluating Gedatolisib in Combination with Palbociclib and Endocrine Therapy at the 2024 San Antonio Breast Cancer Symposium

Celcuity Inc. (NASDAQ:CELC ) Q3 2024 Earnings Conference Call November 14, 2024 4:30 PM ET Company Participants Apoorva Chaloori - ICR Westwicke, Investor Relations Brian Sullivan - Co-Founder & Chief Executive Officer Vicky Hahne - Chief Financial Officer Conference Call Participants Maury Raycroft - Jefferies Brad Canino - Stifel Tara Bancroft - TD Cowen Chase Knickerbocker - Craig Hallum Operator Good afternoon, ladies and gentlemen, and welcome to the Celcuity Third Quarter 2024 Financial Results Conference Call. At this time, all lines are in listen-only mode.

Celcuity Inc. (CELC) Q3 2024 Earnings Call Transcript

MINNEAPOLIS, Nov. 14, 2024 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced financial results for the third quarter ended September 30, 2024 and other recent business developments.

Celcuity Inc. Reports Third Quarter Financial Results and Provides Corporate Update

MINNEAPOLIS, Nov. 12, 2024 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced that Brian Sullivan, Chief Executive Officer, and Co-founder of Celcuity, will present and be available for one-on-one investor meetings at the following investor conferences:

Celcuity Inc. To Present at Upcoming Stifel and Jefferies Investor Conferences

MINNEAPOLIS, Nov. 07, 2024 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced that it will release its financial results for the third quarter 2024 after the market closes on Thursday, November 14, 2024. Management will host a webcast/teleconference the same day at 4:30 p.m. Eastern Time to discuss the results and provide a corporate update.

Celcuity Inc. Schedules Release of Third Quarter 2024 Financial Results and Webcast/Conference Call

The consensus price target hints at an 87.6% upside potential for Celcuity (CELC). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Can Celcuity (CELC) Climb 87.59% to Reach the Level Wall Street Analysts Expect?

Celcuity (CELC) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Celcuity (CELC) Upgraded to Buy: Here's Why

Celcuity Inc. (NASDAQ:CELC ) Q2 2024 Earnings Conference Call August 14, 2024 4:30 AM ET Company Participants Maria Yonkoski - ICR Westwicke, IR Brian Sullivan - Co-Founder and CFO Vicky Hahne - Chief Financial Officer Igor Gorbatchevsky - Chief Medical Officer Conference Call Participants Maury Raycroft - Jefferies Tara Bancroft - TD Cowen Brad Canino - Stifel Operator Good afternoon, ladies and gentlemen, and welcome to the Celcuity Second Quarter 2024 Financial Results Conference Call. At this time all lines are in listen-only mode.

Celcuity Inc. (CELC) Q2 2024 Earnings Call Transcript

MINNEAPOLIS, Aug. 14, 2024 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced financial results for the second quarter ended June 30, 2024 and other recent business developments.

Celcuity Inc. Reports Second Quarter Financial Results and Provides Corporate Update

MINNEAPOLIS, Aug. 07, 2024 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced that it will release its financial results for the second quarter 2024 after the market closes on Wednesday, August 14, 2024. Management will host a webcast/teleconference the same day at 4:30 p.m. Eastern Time to discuss the results and provide a corporate update.

Celcuity Inc. Schedules Release of Second Quarter 2024 Financial Results and Webcast/Conference Call

Celcuity Inc. is a cancer-focused biotech company with one pipeline candidate, gedatolisib, showing promise in breast and prostate cancer. Gedatolisib is a differentiated PI3K inhibitor with a favorable tolerability profile, but faces risks associated with the history of PI3K inhibition in cancer medicine. CELC has a strong cash position to fund key data-related catalysts, but the jump from phase 1 to phase 3 trials carries inherent risks.

Celcuity: Flying A Phase 3 Trial Right Under Your Nose

MINNEAPOLIS, June 03, 2024 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced its participation in the Jefferies Global Healthcare Conference to be held in New York on June 4-6, 2024.

Celcuity To Participate in Jefferies Global Healthcare Conference

MINNEAPOLIS, May 30, 2024 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced the pricing of an underwritten offering of 3,871,000 shares of its common stock at an offering price of $15.50 per share. All of the securities are to be sold by Celcuity. Investors who have agreed to purchase shares in the offering include BVF Partners L.P., a U.S.-based healthcare focused investor, Vivo Capital, Eventide Asset Management, Samlyn Capital, Driehaus Capital Management and Blue Owl Healthcare Opportunities. The offering is expected to close on or about May 31, 2024, subject to satisfaction of customary closing conditions.

Celcuity Announces Pricing of Underwritten Common Stock Offering

MINNEAPOLIS, May 30, 2024 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced that it plans to initiate a Phase 3 clinical trial to evaluate gedatolisib plus a CDK4/6 inhibitor and fulvestrant as first-line treatment for patients with HR+/HER2- advanced breast cancer (“ABC”) who are endocrine therapy resistant. In conjunction with its plan to conduct this study, Celcuity today entered into an amendment to an existing debt facility agreement and received an additional term loan of approximately $62 million.

Celcuity Inc. Announces Plan to Initiate a Phase 3 Clinical Trial for Gedatolisib as First-Line Treatment for HR+/HER2- Advanced Breast Cancer and Secures Approximately $62 Million Debt Financing

Celcuity Inc. (NASDAQ:CELC ) Q1 2024 Earnings Conference Call May 15, 2024 4:30 PM ET Company Participants Maria Yonkoski - ICR Westwicke, IR Brian Sullivan - Co-Founder and CFO Vicky Hahne - Chief Financial Officer Igor Gorbatchevsky - Chief Medical Officer Conference Call Participants Tara Bancroft - TD Cowen Brad Canino - Stifel Gil Blum - Needham & Company Operator Good afternoon, ladies and gentlemen. And welcome the Celcuity First Quarter 2024 Financial Results Conference call.

Celcuity Inc. (CELC) Q1 2024 Earnings Call Transcript

MINNEAPOLIS, May 15, 2024 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced financial results for the first quarter ended March 31, 2024 and other recent business developments.

Celcuity Inc. Reports First Quarter Financial Results and Provides Corporate Update

MINNEAPOLIS, May 08, 2024 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced that it will release its financial results for the first quarter 2024 after the market closes on Wednesday, May 15, 2024. Management will host a webcast/teleconference the same day at 4:30 p.m. Eastern Time to discuss the results and provide a corporate update.

Celcuity Inc. Schedules Release of First Quarter 2024 Financial Results and Webcast/Conference Call

MINNEAPOLIS, April 04, 2024 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced that Brian Sullivan, Chief Executive Officer, and Co-founder of Celcuity, will present and be available for one-on-one investor meetings at the following investor conferences:

Celcuity To Present at Upcoming Needham and Stifel Investor Conferences

Celcuity Inc. (CELC) Q4 2023 Earnings Call Transcript

MINNEAPOLIS, March 27, 2024 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced financial results for the fourth quarter and full year ended December 31, 2023 and other recent business developments.

Celcuity Inc. Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update

Celcuity (CELC) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Why Celcuity (CELC) Might Surprise This Earnings Season

MINNEAPOLIS, March 20, 2024 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced that it will release its financial results for the fourth quarter and full year 2023 after the market closes on Wednesday, March 27, 2024. Management will host a webcast/teleconference the same day at 4:30 p.m. Eastern Time to discuss the results and provide a corporate update.

Celcuity Inc. Schedules Release of Fourth Quarter and Full Year 2023 Financial Results and Webcast/Conference Call

MINNEAPOLIS, March 06, 2024 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced its participation in the Leerink Partners Global Biopharma Conference 2024 to be held in Miami on March 11-13, 2024.

Celcuity to Participate in Leerink Partners Global Biopharma Conference 2024

MINNEAPOLIS, Feb. 28, 2024 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced its participation in Cowen's 44th Annual Health Care Conference to be held in Boston on March 4-6, 2024.

Celcuity to Participate in Cowen's 44th Annual Health Care Conference

MINNEAPOLIS, Feb. 20, 2024 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced the appointment of Eldon Mayer as Chief Commercial Officer. Mr. Mayer joins Celcuity with over 30 years of biopharmaceutical commercial experience in companies ranging from early-stage biotechs to full scale pharmaceutical companies across many therapeutic areas, including oncology.

News for Celcuity Stock (CELC)